|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) | ||
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Options | $ 0.21 | 11/06/2012 | A | 600,000 | 11/06/2012 | 11/06/2022 | Common Stock, $0.001 par value | 600,000 | $ 0 | 600,000 | D | ||||
| Options | $ 0.21 | 11/06/2012 | A | 400,000 | (1) | 11/06/2022 | Common Stock, $0.001 par value | 400,000 | $ 0 | 400,000 | D | ||||
| Options | $ 0.21 | 11/06/2012 | A | 12,500 | 11/06/2012 | 11/06/2022 | Common Stock, $0.001 par value | 12,500 | $ 0 | 12,500 | D | ||||
| Options | $ 0.21 | 11/06/2012 | A | 37,500 | (2) | 11/06/2022 | Common Stock, $0.001 par value | 37,500 | $ 0 | 37,500 | D | ||||
| Reporting Owner Name / Address | Relationships | |||
| Director | 10% Owner | Officer | Other | |
| Cashman Christopher M 11475 GREAT OAKS WAY, SUITE 150 ALPHARETTA, GA 30022 |
X | |||
| /s/ Christopher M. Cashman | 11/13/2012 | |
| **Signature of Reporting Person | Date |
| * | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
| ** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| (1) | The 400,000 options shall vest and become exercisable in increments of 100,000 upon each of the following four events (the "Events"): (i) the first (1st) enrollee in the Company's clinical trial plan, (ii) the twentieth (20th) enrollee, (iii) the fiftieth (50th) enrollee, and (iv) receipt of an FDA approval letter of the dermaPACE device allowance for commercial use; provided, that if the FDA approval letter at subpart (iv) is received prior to the achievement of the enrollment thresholds at subparts (i), (ii), and/or (iii), all options granted under this section but not previously vested shall become vested and immediately exercisable upon receipt of such letter. Any of the Events which have not occurred as of December 31, 2016 shall be considered to have occurred as of December 31, 2016, and all options granted under this section but not previously vested shall become vested and immediately exercisable on such date. |
| (2) | The 37,500 options shall vest and be exercisable based on the following schedule subject to the conditions of the advisory service agreement: (i) 12,500 on February 6, 2013; (ii) 12,500 on May 6, 2013; and, (iii) 12,500 on August 6, 2013. |